The NY Times Co. (NYSE: NYT) has received at least three bids for The Boston Globe for between $65 million and $80 million, according to the Globe. Bidders are: Boston Red Sox owner John Henry, Tampa Tribune owner Robert Loring and former Globe owners the Taylor family.www.boston.com/globe

Mitsubishi Tanabe Pharma Corp. (Tokyo: 4508) has agreed to acquire a 54% stake in Canadian biotech company Medicago Inc. (TSC: MSG) for up to C$179 million. www.medicago.com

William Morris Endeavor is in advanced talks to acquire a 49% stake in New York-based ad agency Droga5 for approximately $225 million, according to the NY Times. www.droga5.com

Schneider Electric (Paris: SU) has offered to acquire British engineering group Invensys PLC (LSE: ISYS) for approximately £3.3 billion. www.invensys.com

EMC Corp. (NYSE: EMC) has agreed to acquire ScaleIO, a Palo Alto, Calif.–based provider of server-side storage software. No financial terms were disclosed. ScaleIO had raised $12 million in VC funding from Greylock IL Partners, Norwest Venture Partners and individual angels. www.scaleio.com

Terreal, a French roof tile and brick-maker, has been taken over by creditors like Goldman Sachs and Park Square Capital, as part of a restructuring package. It had been acquired in 2005 for €860 million by LBO France, ING Bank, Intermediate Capital Group and company management. www.terreal.com

Agios Pharmaceuticals, a Cambridge, Mass.-based developer of cancer metabolism drugs, has set its IPO terms to 5 million common shares being offered at between $14 and $16 per share. It would have an initial market cap of approximately $441 million, were it to price in the middle of its range. Agios plans to trade on the Nasdaq under ticker symbol AGIO, with J.P. Morgan and Goldman Sachs serving as lead underwriters. Shareholders include Third Rock Ventures (23.65% pre-IPO stake), Celgene (17.05%), ARCH Venture Partners (16.41%), Flagship Ventures (16.41%) and Fidelity (9.86%). www.agios.com

Jones Energy Inc., an Austin-based E&P company focused on the Anadarko and Arkoma basins of Texas and Oklahoma, has set its IPO terms to14 million common shares being offered at between $17 and $19 per share. It plans to trade on the NYSE under ticker symbol JONE, with J.P. Morgan serving as lead underwriter. Company shareholders include Metalmark Capital Partners.www.jonesenergy.com

Onconova Therapeutics, a Newtown, Penn.-based cancer drug developer, has set its IPO terms to around 4.6 million common shares being offered at between $12 and $14 per share. It would have an initial market cap of approximately $261 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol ONTX, with Citigroup and Leerink Swann serving as lead underwriters. Baxter International Inc. (NYSE:BAX) holds a 14.7% ownership stake, due to both VC investments and a strategic partnership signed late last year that could be valued at upwards of $565 million. Other VC backers include ICICI Ventures, Mehta Partners and Tinicum Partners. www.onconova.com

Veeva Systems, a Pleasanton, Calif.-based provider of CRM and content management solutions for the biotech, pharma and animal health markets, has filed confidential IPO registration documents with the SEC, according to peHUB. Shareholders include Emergence Capital Partners. www.veeva.com

Sign up for my daily email newsletter on deals and deal-makers: GetTermSheet.com